Arkolith/Insider Trading/ADAP/Form 4

Rawcliffe Adrian

Chief Executive Officer, DirectorAdaptimmune Therapeutics PLC (ADAP) · full profile →Form 4 · filed Jan 15, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$35K
Net Open-Market Flow
-$35K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 15, 2025Sell(S)29K$0.57$17K42K
Jan 13, 2025Sell(S)13K$0.59$7K18K
Jan 13, 2025Sell(S)18K$0.59$11K26K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-003775) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML